What is the optimal management of iron‑deficiency anemia in a 43‑year‑old woman with uterine fibroids scheduled for surgery in one month, given low ferritin and discontinued oral ferrous sulfate?

Optimal Management of Iron-Deficiency Anemia in a 43-Year-Old Woman with Uterine Fibroids Scheduled for Surgery in One Month

This patient requires immediate initiation of intravenous iron therapy rather than restarting oral ferrous sulfate, because heavy uterine bleeding from fibroids creates ongoing blood loss that exceeds the replacement capacity of oral iron, and IV iron will rapidly correct her severe iron depletion before surgery. 1

Why Intravenous Iron is First-Line in This Clinical Scenario

• Heavy uterine bleeding from fibroids is a recognized absolute indication for IV iron rather than oral therapy, because ongoing menstrual blood loss typically exceeds the 65 mg elemental iron that can be absorbed daily from oral ferrous sulfate. 1
• With a ferritin of 7 ng/mL (profoundly depleted stores) and only one month until surgery, IV iron provides rapid repletion that oral iron cannot match within this timeframe—hemoglobin rises by approximately 2 g/dL within 3–4 weeks of IV administration. 2, 3
• The British Society of Gastroenterology explicitly identifies heavy uterine bleeding as a condition where oral iron is inadequate and IV iron is preferred for patients with severe iron deficiency. 1

Recommended Intravenous Iron Regimen

• Ferric carboxymaltose 750 mg IV administered over 15 minutes, repeated once after at least 7 days (total 1500 mg) is the preferred regimen for women ≥50 kg with uterine fibroid-related anemia. 1, 3
• Alternatively, a single 1000 mg dose of ferric carboxymaltose can be given if the patient's weight and iron deficit calculation support this approach. 1, 3
• Modern IV iron formulations like ferric carboxymaltose have serious adverse reaction rates <1:250,000 administrations and allow rapid, high-dose repletion in 1–2 visits. 1
• All IV iron must be administered in a setting equipped with resuscitation facilities, though true anaphylaxis is exceedingly rare (0.6–0.7%). 2

Monitoring Response to IV Iron

• Recheck hemoglobin at 4 weeks post-infusion; an increase of ≥1 g/dL confirms adequate response. 1
• Recheck complete iron studies (ferritin, transferrin saturation) at 8–10 weeks to verify store repletion. 1
• If hemoglobin remains suboptimal or the patient becomes symptomatic before surgery, consider red cell transfusion with a restrictive threshold of hemoglobin 7–8 g/dL only if she develops hemodynamic instability or symptomatic anemia. 1

Why Oral Ferrous Sulfate Was Appropriately Discontinued

• The prior discontinuation of oral ferrous sulfate was likely appropriate because oral iron cannot keep pace with ongoing heavy menstrual blood loss from fibroids—the daily absorption of ~65 mg elemental iron is insufficient when menstrual losses exceed this amount. 1
• Restarting oral iron now would be futile given the one-month surgical timeline and the severity of her iron depletion (ferritin 7 ng/mL). 1

Concurrent Management of the Underlying Cause

• Gynecology consultation should be pursued immediately to optimize fibroid management and potentially reduce bleeding before surgery through medical therapies (e.g., tranexamic acid, hormonal agents, or GnRH analogues). 4, 5, 6
• GnRH agonists used for 3–4 months preoperatively can reduce fibroid size and uterine volume, correct preoperative anemia, and reduce intraoperative blood loss—though the one-month timeline limits their utility in this case. 5
• Anemia must be corrected before elective surgery to reduce perioperative morbidity and transfusion risk. 6

Post-Surgical Iron Management

• After fibroid surgery, continue iron supplementation for 3 months after hemoglobin normalizes to fully replenish stores, with a total treatment duration of 6–7 months. 2
• Monitor hemoglobin and ferritin every 3 months for the first year, then annually, because iron deficiency will likely recur if heavy bleeding persists or returns. 1
• If fibroids are not definitively treated (e.g., myomectomy rather than hysterectomy), regular monitoring every 3 months is essential as recurrent bleeding will deplete iron stores again. 1

Critical Pitfalls to Avoid

• Do not delay IV iron while attempting another trial of oral iron—this is a recognized first-line IV indication, and oral therapy will fail in the setting of ongoing heavy bleeding. 1
• Do not undertransfuse if hemoglobin drops further or the patient becomes symptomatic; transfusion goals of hemoglobin 8–10 g/dL are appropriate for symptomatic patients. 1
• Do not proceed to surgery without correcting anemia—preoperative anemia is independently associated with increased perioperative morbidity and mortality. 7
• Do not assume iron repletion is complete when hemoglobin normalizes; ferritin must be rechecked to confirm adequate store replenishment. 1